Roflumilast Oral Tablet

DRUG4 trials

Sponsors

The University of Hong Kong, Maastricht University, Ganzhou Hemay Pharmaceutical Co., Ltd, Sidra Aziz

Conditions

COPD (Chronic Obstructive Pulmonary Disease)Cerebrovascular DisordersChronic Obstructive Pulmonary Disease With ExacerbationDrug InterventionFunctional RecoveryMemoryNon-cystic Fibrosis Bronchiectasis

Phase 2

Roflumilast in Non-CF Bronchiectasis Study (2019)

CompletedNCT04322929

The University of Hong KongNon-cystic Fibrosis Bronchiectasis

Start: 2020-11-12End: 2024-11-30Updated: 2024-12-09

Roflumilast to Treat Cognitive Sequela After Stroke

CompletedNCT04854811

Maastricht UniversityCerebrovascular Disorders, Drug Intervention, Functional Recovery +1

Start: 2021-07-07End: 2023-12-01Updated: 2024-01-17

A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD

Not yet recruitingNCT07314242

Ganzhou Hemay Pharmaceutical Co., LtdCOPD (Chronic Obstructive Pulmonary Disease)

Start: 2026-01-01End: 2027-12-31Target: 120Updated: 2026-01-02

Phase 4

Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype

Not yet recruitingNCT07795086

Sidra AzizChronic Obstructive Pulmonary Disease With Exacerbation

Start: 2027-02-01End: 2027-02-01Target: 70Updated: 2026-08-31